Neovascularization of the Iris/Angle in Primary Angle Closure Glaucoma: A Distinct Entity!

原发性闭角型青光眼虹膜/房角新生血管形成:一种独特的疾病!

阅读:1

Abstract

AIMS AND BACKGROUND: To describe cases of primary angle closure glaucoma (PACG) with neovascularization of iris/angle (NVI/NVA) with no obvious retinal pathology. CASE DESCRIPTION: We provide a description of three patients with a diagnosis of PACG with NVI/NVA. Detailed history taking along with ophthalmic and systemic examination including slit lamp examination, gonioscopy, and fundus fluorescein angiography (FFA) was done in all patients. FFA revealed peripheral hyperfluorescence and capillary nonperfusion (CNP) areas in periphery in all three eyes. Carotid Doppler and tests for blood coagulation profile were done and no apparent cause of NVI/NVA could be found. Secondary causes of NVI such as proliferative diabetic retinopathy, central retinal vein occlusion, ocular ischemic syndrome (OIS), vasculitis, branch retinal vein occlusion, central retinal artery occlusion, branch retinal artery occlusion, and ocular tumors were ruled out. All these patients had features of angle closure and were hence diagnosed with PACG with NVI/NVA. We hypothesize that chronically raised intraocular pressure (IOP) can result in peripheral retinal ischemia, leading to elevated vascular endothelial growth factor (VEGF) production resulting in NVI/NVA. CONCLUSION: PACG with NVI/NVA in absence of an obvious retinal pathology is a separate clinical entity. NVI without any obvious retinal pathology may occur in cases of PACG on account of development of peripheral retinal nonperfusion. CLINICAL SIGNIFICANCE: PACG with NVI/NVA as per our series seem to have better prognosis than other causes of neovascular glaucoma (NVG). This distinction would help in management and follow-up. Caution should be taken to rule out all other causes. HOW TO CITE THIS ARTICLE: Angmo D, Wajiri GB, Verma S, et al. Neovascularization of the Iris/Angle in Primary Angle Closure Glaucoma: A Distinct Entity!. J Curr Glaucoma Pract 2025;19(4):229-233.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。